logo
Warren Buffett May Soon Reveal Mysterious New Investment

Warren Buffett May Soon Reveal Mysterious New Investment

Newsweeka day ago
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Berkshire Hathaway, the conglomerate led by Warren Buffett, is soon expected to reveal the mystery stock into which his company has reportedly made a significant investment.
This holding could be valued at close to $5 billion, according to Barron's analysis of the company's first- and second-quarter filings.
Why It Matters
Buffett is perhaps the world's most widely revered investor, given the staggering and market-beating returns Berkshire Hathaway has delivered during his six-decade tenure as the conglomerate's chief. As chairman and CEO, Buffett transformed the textile firm into a diversified investment powerhouse with a market cap of $1 trillion.
Major holdings accrued by Berkshire are therefore monitored closely, as these give an insight into the investment strategies of one of the most respected minds in finance. A disclosure of a new stake can grab the attention of investors, who often view Buffett's faith in a company as indicative of its underlying value.
What To Know
Berkshire Hathaway is expected to submit its 13-F report after the closing bell on Thursday. These reports—containing details of a company's equity holdings—are submitted to the U.S. Securities and Exchange Commission typically 45 days after the end of the most recent calendar quarter (June 30), and are one of the few ways the public and fellow investors are able to gain insight into the portfolios and strategies of companies such as Buffett's.
In its quarterly filings, the company discloses its five major holdings— American Express Company, Apple Inc., Bank of America Corporation, The Coca-Cola Company and Chevron Corporation—as well as other major investments. Smaller investments, meanwhile, are divided into three broad categories:
Banks, insurance and finance;
Consumer products;
Commercial, industrial and other.
As Barron's reports, the cost basis—original asset value—of the third category rose by $2 billion in the first quarter and $2.8 billion in the second quarter, suggesting that Berkshire's could have purchased up to $4.8 billion of the mystery stock or stocks.
Warren Buffett, Chairman and CEO of Berkshire Hathaway, makes his way to a morning session at the Allen & Company Sun Valley Conference on July 13, 2023 in Sun Valley, Idaho.
Warren Buffett, Chairman and CEO of Berkshire Hathaway, makes his way to a morning session at the Allen & Company Sun Valley Conference on July 13, 2023 in Sun Valley, Idaho.The outlet noted that Berkshire requested confidential treatment for at least one stock purchased during the first quarter, and that it could do so in the upcoming 13-F, meaning this could remain a mystery for a while longer.
The last time Berkshire requested confidentiality treatment—which withholds information from the public and allows institutional investors to build positions without tipping off the market and triggering copycat trades—was in late 2023. Berkshire was able to secretly build up a significant position in the insurance giant Chubb, having been granted permission to delay this disclosure until May 2024, at which point its stake was worth $6.7 billion.
When Berkshire's holding in Chubb was finally revealed, the stock rose over 4 percent and reached what was then a record high, according to the Wall Street Journal.
What People Are Saying
Financial and investing advice firm The Motley Fool wrote in June: "The reason a fund manager would request [confidential treatment] is because investors would pile in and drive up the share price if the position were publicly revealed. If a high-profile money manager with a sizable Wall Street following can quietly build up their stake in a public company, they can likely do so at an advantageous price."
It added that there were 54 potential candidates for the mystery stock, including UPS, FedEx and Caterpillar.
What Happens Next?
As Barron's noted, investors may have to wait until mid-November, when the company files its 13-F for the third quarter, to discover the provenance of the mystery stocks.
Buffett is set to step down from his role as Berkshire's CEO at the end of the year, and announced in May that he will be handing the reins over to Greg Abel, vice chair of non-insurance operations.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lennox International Stock Outlook: Is Wall Street Bullish or Bearish?
Lennox International Stock Outlook: Is Wall Street Bullish or Bearish?

Yahoo

time38 minutes ago

  • Yahoo

Lennox International Stock Outlook: Is Wall Street Bullish or Bearish?

Lennox International Inc. (LII), headquartered in Richardson, Texas, designs, manufactures, and markets products for the heating, ventilation, air conditioning, and refrigeration markets. Valued at $20.7 billion by market cap, the company sells its products and services through direct sales, distributors, and company-owned parts and supplies stores. Shares of this leader in energy-efficient climate-control solutions have underperformed the broader market over the past year. LII has gained 5.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.6%. In 2025, LII's stock is down 3.1%, compared to the SPX's 9.6% rise on a YTD basis. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Narrowing the focus, LII's underperformance is also apparent compared to the Industrial Select Sector SPDR Fund (XLI). The exchange-traded fund has gained about 22.9% over the past year. Moreover, the ETF's 15.3% gains on a YTD basis outshine LII's single-digit dip over the same time frame. On Jul. 23, LII shares closed up by 6.6% after reporting its Q2 results. Its revenue stood at $1.5 billion, up 3.4% year over year. The company's adjusted EPS increased 14.5% from the year-ago quarter to $7.82. For the current fiscal year, ending in December, analysts expect LII's EPS to grow 6.4% to $24.02 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 17 analysts covering LII stock, the consensus is a 'Hold.' That's based on six 'Strong Buy' ratings, six 'Holds,' one 'Moderate Sell,' and four 'Strong Sells.' The configuration has been consistent over the past three months. On Aug. 1, Joe O'Dea from Wells Fargo & Company (WFC) maintained a 'Sell' rating on LII with a price target of $675, implying a potential upside of 14.3% from current levels. The mean price target of $670.93 represents a 13.6% premium to LII's current price levels. The Street-high price target of $754 suggests an ambitious upside potential of 27.7%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio

Cencora Stock: Analyst Estimates & Ratings
Cencora Stock: Analyst Estimates & Ratings

Yahoo

time38 minutes ago

  • Yahoo

Cencora Stock: Analyst Estimates & Ratings

Valued at a market cap of $56 billion, Cencora, Inc. (COR) sources and distributes pharmaceutical products for people and animals. The Conshohocken, Pennsylvania-based company provides essential support, encompassing clinical trial logistics and consulting to packaging, data analytics, and patient adherence programs. This healthcare company has outpaced the broader market over the past 52 weeks. Shares of COR have surged 21.6% over this time frame, while the broader S&P 500 Index ($SPX) has gained 20.6%. Moreover, on a YTD basis, the stock is up 28.7%, compared to SPX's 9.6% return. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Zooming in further, COR's outperformance looks even more pronounced when compared to the VanEck Pharmaceutical ETF's (PPH) 11% loss over the past 52 weeks and 3.2% YTD drop. On Aug. 6, Cencora released its Q3 results. Due to growth in both its U.S. and International healthcare solutions segments, the company's overall revenue improved 8.7% year-over-year to $80.7 billion, surpassing consensus estimates by a slight margin. Moreover, its adjusted EPS of $4 advanced 19.8% from the prior-year quarter and came in 5.8% above analyst expectations. Additionally, COR raised its fiscal 2025 adjusted EPS guidance, and now expects it to be between $15.85 and $16. Yet, its shares tumbled 2.9% after the earnings release. For the current fiscal year, ending in September, analysts expect COR's EPS to grow 15.9% year over year to $15.95. The company's earnings surprise history is promising. It surpassed the consensus estimates in each of the last four quarters. Among the 14 analysts covering the stock, the consensus rating is a "Strong Buy' which is based on 11 'Strong Buy,' and three 'Hold' ratings. This configuration is slightly more bullish than three months ago, with 10 analysts suggesting a 'Strong Buy' rating. On Aug. 11, JPMorgan Chase & Co. (JPM) analyst Richard Choe maintained a "Buy" rating on COR and set a price target of $344, implying a 19% potential upside from the current levels. The mean price target of $335 represents a 15.9% premium from COR's current price levels, while the Street-high price target of $355 suggests an ambitious upside potential of 22.8%. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Are Wall Street Analysts Predicting Yum! Brands Stock Will Climb or Sink?
Are Wall Street Analysts Predicting Yum! Brands Stock Will Climb or Sink?

Yahoo

time38 minutes ago

  • Yahoo

Are Wall Street Analysts Predicting Yum! Brands Stock Will Climb or Sink?

Louisville, Kentucky-based Yum! Brands, Inc. (YUM) develops, operates, franchises, and licenses quick service restaurants. Valued at $39.2 billion by market cap, the company prepares, packages, and sells a menu of food items. Shares of this fast-food company have underperformed the broader market over the past year. YUM has gained 4.8% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.6%. In 2025, YUM's stock rose 5.9%, compared to the SPX's 9.6% rise on a YTD basis. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Narrowing the focus, YUM's underperformance is also apparent compared to the AdvisorShares Restaurant ETF (EATZ). The exchange-traded fund has gained about 16.6% over the past year. However, YUM's gains on a YTD basis outshine the ETF's 1.5% returns over the same time frame. On Aug. 5, YUM shares closed down more than 5% after reporting its Q2 results. Its adjusted EPS of $1.44 did not meet Wall Street expectations of $1.45. The company's revenue was $1.9 billion, matching Wall Street forecasts. For the current fiscal year, ending in December, analysts expect YUM's EPS to grow 9.3% to $5.99 on a diluted basis. The company's earnings surprise history is mixed. It beat the consensus estimate in two of the last four quarters while missing the forecast on two other occasions. Among the 27 analysts covering YUM stock, the consensus is a 'Moderate Buy.' That's based on nine 'Strong Buy' ratings, and 18 'Holds.' This configuration is more bullish than two months ago, with eight analysts suggesting a 'Strong Buy.' On Aug. 6, Gregory Francfort from Guggenheim reiterated a 'Buy' rating on YUM with a price target of $167, implying a potential upside of 17.5% from current levels. The mean price target of $160.65 represents a 13.1% premium to YUM's current price levels. The Street-high price target of $185 suggests an ambitious upside potential of 30.2%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store